High Dose
High dose therapy in poor risk primary breast cancer (C/10/92)
This Study is closed to recruitment
Aim of the study:
To evaluate the disease free survival and overall survival of poor prognosis primary breast cancer patients receiving high dose chemotherapy compared with a more conventional adjuvant chemotherapy regimen.
Study Regimen:
End Point:
The main end point used for evaluation, will be overall survival based on all cause mortality. Relapse free survival, breast cancer mortality and cardiovascular mortality will also be assessed.
Recruitment:
Recruitment closed in July 2001 - Final Accrual into the main study: 281
Status:
This is a closed trial in active long term follow-up.
Contact:
For further information please contact the ICCG centre:
ICCG Data Centre
Department of Medical Oncology
Charing Cross Hospital
Fulham Palace Road
London
W6 8RF
Fax: (+44) 20 8846 1206
Email: iccg@imperial.ac.uk
Publications:
- R C Coombes, J M Bliss, A Howell, M Emson, C Peckitt, C Gallagher, C Bengala, A Tres, R.Welch, P Lawton, R Rubens, E Woods, J Haviland, D Vigushin, E Kanfer, on behalf of the International Collaborative Cancer Group. High Dose Chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial. Annals of Oncology 16: 726-734, 2005
